Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?

Pharmacoepidemiology and Drug Safety

Volumn 5, Issue 5, 1996, Pages 285-294

  Heinemann, Lothar A J ^a,d   Lewis, Michael A ^b,d   Assmann, Anita ^a   Gravens, Lisa ^a   Guggenmoos Holzmann, Irene ^c,d  

^a ZEG Ctr Epidemiol and Hlth Res   (Germany)

^b Potsdam Inst P   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Drug utilization; EpidemioIogical study; Oral contraceptives

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; DRUG USE; FEMALE; HUMAN; PHARMACOEPIDEMIOLOGY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; THROMBOSIS;

EID: 0029903711     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199609)5:5<285::AID-PDS236>3.0.CO;2-T     Document Type: Article

References (8)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1581.
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
3. Bloemenkamp, K. W. M., Rosendaal, F. R., Helmerhorst, F. M., Büller, H. R. and Vandenbrouke, J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596.
4. Spitzer, W. O., Lewis, M. A., Heinemann, L. A. J., Thorogood, M. and MacRae, K. D. Third generation oral contraceptives and risk of venous thromboembolic disorders - an international case-control study. British Medical Journal 1996; 312: 83-88.
5. Jick, H., Jick, S. S., Gurevich, V., Myers, M. W. and Vasilakis, C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
6. Lewis, M. A., Spitzer, W. O., Heinemann, L. A. J., MacRae, K. D., Bruppacher, R. and Thorogood, M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. British Medical Journal 1996; 312: 88-90.
7. Schlesselman, J. J. Case Control Studies Design, Conduct, Analysis. Oxford University Press, Inc., Oxford, 1982.
8. Martin Hamblin Research. A Presentation to the Committee for Proprietary Medicinal Products of the EMEA, unpublished report, 1995.